Trial Profile

Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30%

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 18 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alvocidib (Primary) ; Cytarabine; Mitoxantrone
Indications Acute myeloid leukaemia
Focus Therapeutic Use
Acronyms Zella 201
Sponsors Sumitomo Pharma Oncology; Tolero Pharmaceuticals

Most Recent Events

08 Dec 2020 Results (n=13) of newly diagnosed high-risk exploratory arm, presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
05 Dec 2020 Results presented in a Sumitomo Dainippon Pharma media release.
05 Dec 2020 According Sumitomo Dainippon Pharma media release, data from this trial were presented at 62nd American Society of Hematology Annual Meeting

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com